201 related articles for article (PubMed ID: 25281165)
1. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry.
Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R
Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
3. Derivatization with 2-hydrazino-1-methylpyridine enhances sensitivity of analysis of 5α-dihydrotestosterone in human plasma by liquid chromatography tandem mass spectrometry.
Faqehi AM; Denham SG; Naredo G; Cobice DF; Khan S; Simpson JP; Sabil G; Upreti R; Gibb F; Homer NZ; Andrew R
J Chromatogr A; 2021 Mar; 1640():461933. PubMed ID: 33588275
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
5. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
6. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
7. Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient.
Yuan L; Ding M; Ma J; Xu J; Wu X; Feng J; Shen F; Zhou X
Eur J Drug Metab Pharmacokinet; 2011 Jan; 35(3-4):137-46. PubMed ID: 21302041
[TBL] [Abstract][Full Text] [Related]
8. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
9. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
Stuart JD; Lee FW; Simpson Noel D; Kadwell SH; Overton LK; Hoffman CR; Kost TA; Tippin TK; Yeager RL; Batchelor KW; Bramson HN
Biochem Pharmacol; 2001 Oct; 62(7):933-42. PubMed ID: 11543729
[TBL] [Abstract][Full Text] [Related]
11. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
12. 5α-reductase type 1 modulates insulin sensitivity in men.
Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464
[TBL] [Abstract][Full Text] [Related]
13. A direct assay for the routine measurement of testosterone, androstenedione, dihydrotestosterone and dehydroepiandrosterone by liquid chromatography tandem mass spectrometry.
Owen LJ; Wu FC; Büttler RM; Keevil BG
Ann Clin Biochem; 2016 Sep; 53(Pt 5):580-7. PubMed ID: 26589631
[TBL] [Abstract][Full Text] [Related]
14. Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors.
Olsson Gisleskog P; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Eur J Pharm Sci; 1999 Aug; 8(4):291-9. PubMed ID: 10425379
[TBL] [Abstract][Full Text] [Related]
15. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific.
Chhipa RR; Halim D; Cheng J; Zhang HY; Mohler JL; Ip C; Wu Y
Prostate; 2013 Oct; 73(14):1483-94. PubMed ID: 23813737
[TBL] [Abstract][Full Text] [Related]
16. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results.
Traish AM; Krakowsky Y; Doros G; Morgentaler A
Sex Med Rev; 2019 Jan; 7(1):95-114. PubMed ID: 30098986
[TBL] [Abstract][Full Text] [Related]
17. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
18. The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.
Mačukat IR; Spanjol J; Orlič ZC; Butorac MZ; Marinovič M; Ćupič DF
Coll Antropol; 2014 Sep; 38(3):835-9. PubMed ID: 25420363
[TBL] [Abstract][Full Text] [Related]
19. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
20. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
